Welcome to our dedicated page for Edap Tms SEC filings (Ticker: EDAP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to pinpoint HIFU sales trends or FDA clearance milestones inside EDAP’s dense disclosures? The company’s multi-division model—robotic high-intensity focused ultrasound, extracorporeal lithotripsy, and third-party distribution—produces technical documents packed with clinical data and global regulatory notes, making EDAP SEC filings explained simply a real need.
Stock Titan decodes every document as soon as it hits EDGAR. Our AI-powered summaries turn an EDAP annual report 10-K simplified into a five-minute read, flagging segment revenue, backlogged orders, and device approval status. Want the latest quarter? The EDAP quarterly earnings report 10-Q filing arrives with instant ratio analysis and plain-English commentary. Form types are mapped to real investor questions:
- EDAP 8-K material events explained for sudden trial outcomes
- EDAP insider trading Form 4 transactions with price and volume details
- EDAP proxy statement executive compensation breakdowns
Need real-time alerts? EDAP Form 4 insider transactions real-time pings you the moment executives trade. Curious about the impact of a new Focal One installation? Our EDAP earnings report filing analysis connects revenue changes to installed-base growth. From understanding EDAP SEC documents with AI to tracking EDAP executive stock transactions Form 4, you can move from document dump to decision in minutes—while retaining the original filing for audit trails.
Investar Holding Corporation (NASDAQ: ISTR) has entered into two material transactions that reshape its capital structure and growth trajectory.
1. Acquisition of Wichita Falls Bancshares (WFB)
• On 1 July 2025, Investar signed a definitive Agreement and Plan of Merger to acquire WFB, parent of First National Bank, Wichita Falls, TX.
• Consideration: $7.2 million cash plus 3,955,344 ISTR shares; based on 30 June 2025 close of $19.32, total value is ≈ $83.6 million.
• Post-close, WFB will merge into Investar; the bank subsidiary will merge into Investar Bank, N.A.
• Deal approved unanimously by both boards; expected closing: Q4 2025, subject to customary shareholder and regulatory approvals.
• Key protections: no-shop clause with matching right, outer termination date of 31 Mar 2026 (extendable to 30 Jun 2026 for regulatory delay), and a $3.3 million breakup fee payable by WFB under specified circumstances.
2. Capital Raise – Series A Preferred Stock Private Placement
• Concurrently, Investar executed a Securities Purchase Agreement to sell 32,500 shares of newly created 6.5% Series A Non-Cumulative Perpetual Convertible Preferred Stock at $1,000 per share.
• Gross proceeds: $32.5 million; estimated net proceeds: ≈ $30.4 million.
• Purpose: finance the WFB acquisition, support organic growth, and maintain capital ratios. The preferred is intended to qualify as additional Tier 1 capital.
• The preferred is perpetual, ranks senior to common, carries a 6.5% quarterly dividend (non-cumulative), is optionally redeemable after 1 July 2030, and convertible at the holder’s option into ISTR common at 47.619 shares per preferred share (≈ $21.00 implied conversion price), subject to a 1.6 million share cap.
• Mandatory conversion right for Investar after 1 July 2028 if the common stock trades above $26.25 for 20 of 30 consecutive trading days.
• Registration rights require Investar to file a resale shelf within 60 days of closing; shares are sold under Rule 506(b).
Strategic Rationale and Impact
• The acquisition adds a Texas franchise, deepening Investar’s Gulf South footprint and diversifying its loan/deposit base.
• Stock consideration represents roughly 36% of Investar’s current shares outstanding (≈10.9 m), implying meaningful dilution but preserving regulatory capital.
• The preferred raise back-stops the cash portion and transaction costs while boosting CET1 through AT1 treatment.
• Closing risk includes regulatory approvals, integration execution, and potential dilution from both the acquisition shares and future preferred conversions.